Share

FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT...
Share

At Arm’s Length: A Look at a New Mealtime, Injection-Free Insulin Patch

Priyanka Majety, MD, discusses a new, FDA-approved wearable insulin-delivery patch that could potentially improve patients’ insulin adherence as well as their quality of life. Last summer, a wearable patch designed for mealtime insulin delivery (in lieu of traditional injections) received clearance from the U.S. Food and Drug Administration, extending the patch’s wear time from three...
Share

Classic Congenital Adrenal Hyperplasia Supplement Published in The Journal of Clinical Endocrinology & Metabolism

Last month, The Journal of Clinical Endocrinology and Metabolism published a classic congenital adrenal hyperplasia (CAH)-focused supplement, titled “Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime.” The supplement contains eight review articles that provide a comprehensive look at the clinical, psychosocial, treatment-related and day-to-day challenges...
Share

High Time: Addressing Research Gaps in Opioid-Associated Endocrine Conditions

Endocrine News speaks with Niki Karavitaki, MSc, PhD, FRCP, of the University of Birmingham, Birmingham Health Partners, and the University Hospitals Birmingham National Health Service Foundation Trust in Birmingham, U.K., chair of the Endocrine Society’s recent Scientific Statement on opioids’ impact on the endocrine system. She discusses gaps in research, as well as why healthcare...
Share

Standardized Testing: Universal Risk Stratification System Needed for Thyroid Nodules

With thyroid cancer patients often getting different — and sometimes conflicting — treatment recommendations from a variety of diagnostic tools, Priyanka Majety, MD, talks to Endocrine News about why it’s time for clinicians to coalesce around a single set of standards for these cases, which could potentially eliminate unnecessary procedures. Priyanka Majety, MD, assistant professor...